NAB1

NAB1 is a nuclear transcriptional corepressor that selectively restrains the Egr family of immediate-early transcription factors (PMID:7624335). It functions not by blocking DNA binding or nuclear import of its targets but as an active repressor: it docks onto the inhibitory domain of Egr factors such as NGFI-A/Egr-1 and Krox20/Egr2 — while sparing other family members like Egr3 — thereby positioning its intrinsic repressor activity at the transcription unit (PMID:7624335, PMID:11018254). This repressor activity resides in the conserved C-terminal NCD2 domain and is position-independent: when tethered directly to DNA, NAB1 silences constitutively active promoters regardless of promoter identity, enhancer presence, or distance from its binding site (PMID:9418898, PMID:11018254). NAB1 expression is itself inducible by anti-inflammatory signals — aspirin-triggered lipoxin A4 analog upregulates it through a pertussis-toxin-sensitive G protein-coupled receptor pathway (PMID:11687510) — and in chondrocytes valproic acid recruits NAB1 to the mPGES-1 promoter to suppress IL-1β-induced mPGES-1 transcription (PMID:21239760), linking its corepressor function to control of inflammatory gene expression. Screening of peripheral neuropathy patients found no disease-causing NAB1 mutations, indicating it is not a common cause of inherited peripheral neuropathy (PMID:12030330).

1. 1995 High

   Established that a dedicated nuclear partner exists to selectively regulate the Egr transcription factor family, answering how Egr-driven transcription is dampened.

   Evidence Yeast two-hybrid screen against the NGFI-A inhibitory domain plus transcriptional repression assays in cells

   PMID:7624335

   Open questions at the time

   • Did not define the molecular mechanism of repression
   • Did not map the repressor domain of NAB1
   • Basis for selectivity (Egr-1/Krox20 vs Egr3/NGFI-G) not resolved
2. 1998 High

   Resolved that NAB1 acts as an active repressor rather than a passive blocker, and localized this activity to a discrete domain.

   Evidence Replacement mutagenesis of NCD2 and DNA-tethered (heterologous) repression assays, plus nuclear localization sequence mapping

   PMID:9418898

   Open questions at the time

   • Corepressor machinery recruited by NCD2 not identified
   • No structural model of the NCD2 repression domain
3. 2000 Medium

   Confirmed the docking logic — the Egr-1 inhibitory domain serves as the recruitment site bringing NAB1's position-independent repressor activity to the promoter.

   Evidence GAL4-NAB1 fusion repression assays from proximal and distal positions and overexpression studies in transient transfection

   PMID:11018254

   Open questions at the time

   • Single-lab functional assays without structural confirmation of the interaction interface
   • Endogenous target genes not surveyed
4. 2001 Medium

   Placed NAB1 downstream of an anti-inflammatory lipid-mediator signaling pathway, connecting its expression to GPCR-driven control.

   Evidence Differential display RT-PCR with pertussis toxin blockade in human neutrophils and in vivo expression in murine lung vascular smooth muscle

   PMID:11687510

   Open questions at the time

   • Specific GPCR mediating induction not identified
   • Functional consequence of induced NAB1 on inflammatory transcription not assessed in this work
5. 2011 Medium

   Demonstrated an endogenous promoter target and a causal role for NAB1 in suppressing inflammatory gene expression.

   Evidence ChIP showing NAB1 recruitment to the mPGES-1 promoter and siRNA knockdown abolishing valproic-acid-mediated suppression in human chondrocytes

   PMID:21239760

   Open questions at the time

   • Whether recruitment requires an Egr factor at the mPGES-1 promoter not directly tested
   • Single cell type and single lab
   • Corepressor complex composition at this promoter unknown
6. 2002 Medium

   Tested and excluded NAB1 as a frequent genetic cause of inherited peripheral neuropathy.

   Evidence Mutation screening of EGR2-interacting domains and full coding region in 87 neuropathy patients

   PMID:12030330

   Open questions at the time

   • Negative result does not exclude rare or regulatory variants
   • Does not address NAB1 function in nervous system development

• The corepressor effector machinery NAB1 recruits through NCD2 and the structural basis of its Egr-domain docking remain unidentified in this corpus.
• No interactome of the NCD2 repression module
• No structure of the NAB1–Egr inhibitory domain complex
• Genome-wide endogenous target gene set undefined